MIVI.OTCBB
Current Price: US $1.30   Change: -0.01
Home Contact Us Careers Corporate Technology Trials Investors News Releases

News Releases

2008 News Releases
2007 News Releases
2006 News Releases
Aug 5, 2008
MIV Announces Excellent Safety and Efficacy of VESTAsynctm Polymer-Free Drug-Eluting Stent at 12-Month Clinical Follow Up


Jul 30, 2008
Miv Therapeutics To Present At The BMO Capital Markets Focus On Healthcare Conference


Jul 29, 2008
MIV Therapeutics’ CEO, Mark Landy Joins Distinguished Leaders


Jul 16, 2008
MIV Provides Update On Its Next -Generation, Ultra-Thin ProteaTM Stent Platform


Jul 14, 2008
MIV Announces Jesup & Lamont Buy Recommendation and Revises MIV Target Price to Reflect Reverse Split


Jun 30, 2008
MIV Announces Effectiveness Of 1-For-10 Reverse Stock Split


Jun 16, 2008
MIV Board Approves One-For-10 Reverse Stock Split


Jun 6, 2008
MIV Therapeutics Featured in Scientific American Online


May 21, 2008
First Patients Enrolled in MIV Therapeutics VESTASYNC II Study


May 20, 2008
MIV's Stents Subject of Two Live Cases and Several Presentations at Europcr


May 6, 2008
MIV Therapeutics Featured In Cardiovascular Business News


May 5, 2008
MIV’s Vestasync™ Polymer-Free Drug-Eluting Stent To Be Highlighted At Several Presentations At Europcr


Mar 31, 2008
MIV Preliminary Nine-Month Human Data Affirms Excellent Safety and Efficacy of VESTAsyncTM Polymer-Free Drug-Eluting Stent


Mar 24, 2008
MIV to Present Preliminary 9-Month Fim Data for the Vestasync Polymer-Free Drug-Eluting Stent


Mar 4, 2008
MIV Therapeutics Announces Changes to its Scientific Advisory Board


Feb 22, 2008
MIV Therapeutics Receives 2008 Frost & Sullivan North America Award For Technology Innovation


Jan 7, 2008
MIV Therapeutics Appoints Mark Landy to Additional Post of Chief Executive Officer
Designed and Powered by Blender Media
Copyright 2007 © MIV Therapeutics Inc.